Skip to main content

Table 2 Univariate and multivariate associations of EGFR mutation and FISH status, clinicopathological characteristics, and status of other seven genes with PFS and OS in the total of 416 NSCLC patients

From: Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations

Variable

PFS

OS

Univariate

Multivariate

Univariate

Multivariate

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

Age

 ≤ 60

1

     

1

     

 > 60

1.01

0.82–1.25

0.913

   

1.21

0.94–1.57

0.145

   

Gender

 Male

1

  

1

  

1

  

1

  

 Female

0.59

0.48–0.73

< 0.001

0.56

0.42–0.74

< 0.001

0.59

0.45–0.76

< 0.001

0.65

0.48–0.94

0.006

Smoking status

 Smoking

1

  

1

  

1

  

1

  

 No smoking

0.60

0.48–0.74

< 0.001

0.64

0.50–0.81

< 0.001

0.62

0.48–0.80

< 0.001

0.79

0.58–1.06

0.113

Histology

 Non-ADC

1

  

1

  

1

     

 ADC

0.67

0.52–0.86

0.002

0.84

0.64–1.10

0.203

0.78

0.58–1.07

0.122

   

Differentiation

 High to medium

1

  

1

  

1

     

 Low

1.36

1.11–1.68

0.004

0.89

0.72–1.18

0.299

1.12

0.87–1.44

0.363

   

Stage

 Recurrent

1

     

1

     

 IIIB and IV

0.88

0.70–1.10

0.254

   

0.83

0.63–1.09

0.183

   

Line of TKI therapy

 2, 3

1

  

1

  

1

  

1

  

 1

0.68

0.53–0.87

0.002

0.75

0.58–0.97

0.027

0.67

0.50–0.90

0.009

0.78

0.57–1.05

0.103

ECOG PS

 2

1

  

1

  

1

  

1

  

 0, 1

0.71

0.52–0.95

0.023

0.73

0.54–0.99

0.043

1.71

1.17–2.48

0.004

0.62

0.43–0.90

0.011

EGFR mutation

 Mt

1

  

1

  

1

  

1

  

 Wt

0.38

0.31–0.47

< 0.001

0.54

0.42–0.70

< 0.001

0.50

0.38–0.65

< 0.001

0.63

0.47–0.85

0.002

EGFR copy number

 FISH−

1

  

1

  

1

  

1

  

 FISH+

0.54

0.43–0.67

< 0.001

0.67

0.54–0.84

0.001

0.60

0.46–0.78

< 0.001

0.77

0.58–1.02

0.068

ALK

 Wt

1

  

1

  

1

  

1

  

 Apart

2.06

1.41–3.02

< 0.001

1.41

0.93–2.16

0.105

1.59

1.00–2.51

0.047

1.34

0.82–2.17

0.240

BIM

 Wt

1

     

1

     

 Deletion

0.89

0.58–1.36

0.596

   

1.05

0.64–1.71

0.856

   

KRAS mutation

 Wt

1

  

1

  

1

     

 Mt

1.99

1.33–2.99

0.001

1.21

0.79–1.84

0.386

1.55

0.97–2.47

0.070

   

PIK3CA mutation

 wt

1

     

1

     

 mt

1.18

0.61–2.29

0.619

   

1.22

0.60–2.47

0.583

   

PTEN copy number

 Intact

1

     

1

     

 Deletion

1.54

0.99–2.39

0.058

   

1.06

0.64–1.77

0.811

   

PTEN expression

 Normal

1

  

1

  

1

     

 Low expression

1.37

1.08–1.74

0.011

1.10

0.86–1.42

0.439

1.12

0.84–1.50

0.448

   

MET copy number

 FISH−

1

  

1

  

1

  

1

  

 FISH+

1.87

1.35–2.60

< 0.001

1.51

1.07–2.13

0.019

1.64

1.14–2.37

0.008

1.47

1.01–2.13

0.045

MET expression

 MAb−

1

     

1

     

 MAb+

1.01

0.79–1.28

0.955

   

1.18

0.87–1.59

0.283

   

MET expression

 H-score−

1

     

1

     

 H-score+

1.14

0.93–1.40

0.217

   

0.97

0.75–1.25

0.805

   

IGF1R copy number

 FISH−

1

  

1

  

1

     

 FISH+

1.40

1.05–1.87

0.019

1.07

0.78–1.46

0.688

1.10

0.77–1.57

0.619

   

IGF1R expression

 IHC−

1

     

1

     

 IHC+

1.26

0.99–1.61

0.062

   

1.05

0.78–1.40

0.770

   
  1. ADC adenocarcinoma, ECOG Eastern cooperative oncology group, TKI tyrosine kinase inhibitors, FISH fluorescent in situ hybridization, HR hazard ratio, CI confidence interval, PFS progression-free survival, OS overall survival
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us